Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma

Jacob E. Till; Ofer Gal-Rosenberg; Sophia G. Giliberto; Nicholas J. Seewald; Dominique G. Ballinger; Heather E. Samberg; Melinda R. Yin; Qiao-Li Wang; Samuele Cannas; Kristine N. Kim; Kyle Tien; Mohammed Sawi; Vidya Madineedi; C. Sloane Furniss; Vasilena Gocheva; Jonathan Nowak; Lauren K. Brais; Chen Yuan; Michael H. Rosenthal; Robert Roses; Ronald DeMatteo; Major Kenneth Lee; Charles Vollmer; Hersh Sagreiya; Mark H. O'Hara; Ruth Shemer; Brian Wolpin; Yuval Dor; Erica L. Carpenter

doi:10.1002/ctm2.70573

Clinical and Translational Medicine ›› 2026, Vol. 16 ›› Issue (1) :e70573 DOI: 10.1002/ctm2.70573

LETTER TO THE JOURNAL

Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma

Author information +

¹. Department of Medicine, Division of Haematology-Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

². Department of Developmental Biology and Cancer Research, Hebrew University Institute for Medical Research, Israel-Canada, Jerusalem, Israel

³. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

⁴. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

⁵. Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

⁶. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA

⁷. Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA

⁸. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

⁹. Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

erical@upenn.edu

Show less

History +

PDF

Cite this article

Download citation ▾

Jacob E. Till, Ofer Gal-Rosenberg, Sophia G. Giliberto, Nicholas J. Seewald, Dominique G. Ballinger, Heather E. Samberg, Melinda R. Yin, Qiao-Li Wang, Samuele Cannas, Kristine N. Kim, Kyle Tien, Mohammed Sawi, Vidya Madineedi, C. Sloane Furniss, Vasilena Gocheva, Jonathan Nowak, Lauren K. Brais, Chen Yuan, Michael H. Rosenthal, Robert Roses, Ronald DeMatteo, Major Kenneth Lee, Charles Vollmer, Hersh Sagreiya, Mark H. O'Hara, Ruth Shemer, Brian Wolpin, Yuval Dor, Erica L. Carpenter. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Clinical and Translational Medicine, 2026, 16(1): e70573 DOI:10.1002/ctm2.70573

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Daamen LA, Dorland G, Brada LJH, et al. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. HPB. 2022; 24: 535-546.

[2]	Crippa S, Malleo G, Mazzaferro V, et al. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. JAMA Surg. 2024; 159: 1139-1147.

[3]	Ben-Ami R, Wang Q-L, Zhang J, et al. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024; 73: 639-648.

[4]	Black JRM, Bartha G, Abbott CW, et al. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nat Med. 2025; 31: 70-76.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.